AU4485089A - Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr - Google Patents

Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr

Info

Publication number
AU4485089A
AU4485089A AU44850/89A AU4485089A AU4485089A AU 4485089 A AU4485089 A AU 4485089A AU 44850/89 A AU44850/89 A AU 44850/89A AU 4485089 A AU4485089 A AU 4485089A AU 4485089 A AU4485089 A AU 4485089A
Authority
AU
Australia
Prior art keywords
tcr
antibodies
activation
growth
human tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44850/89A
Inventor
Timothy Eberlein
Deric D. Schoof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU4485089A publication Critical patent/AU4485089A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU44850/89A 1988-10-21 1989-09-27 Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr Abandoned AU4485089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26071688A 1988-10-21 1988-10-21
US260716 1988-10-21

Publications (1)

Publication Number Publication Date
AU4485089A true AU4485089A (en) 1990-05-14

Family

ID=22990313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44850/89A Abandoned AU4485089A (en) 1988-10-21 1989-09-27 Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr

Country Status (2)

Country Link
AU (1) AU4485089A (en)
WO (1) WO1990004633A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633940B2 (en) * 1989-07-21 1993-02-11 Ortho Pharmaceutical Corporation Method for stimulating proliferation of peripheral blood lymphocytes

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2618497B2 (en) * 1989-10-03 1997-06-11 鐘淵化学工業株式会社 Tumor-damaging cell inducer and tumor-damaging cell induction device
ZA92304B (en) * 1991-01-16 1992-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
DE69433087T2 (en) * 1993-06-11 2004-06-09 Coulter International Corp., Miami ANTI-CD3 ANTIBODY AMINODEXTRAN CONJUGATES FOR INDUCTION OF T CELL ACTIVATION AND PROPAGATION
BR112020018658A2 (en) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633940B2 (en) * 1989-07-21 1993-02-11 Ortho Pharmaceutical Corporation Method for stimulating proliferation of peripheral blood lymphocytes

Also Published As

Publication number Publication date
WO1990004633A1 (en) 1990-05-03

Similar Documents

Publication Publication Date Title
GB2220211B (en) Modified lipopolysaccharides and process of preparation
AU3758289A (en) Improvements in and relating to protein products
AU604958B2 (en) Human serum albumin crystals and method of preparation
AU4418789A (en) Synthesis of camptothecin and analogs thereof
AU3212689A (en) Medical material permitting cells to enter thereinto and artificial skin
NZ231803A (en) Transforming growth factor-beta2 and its preparation via recombinant techniques
AU1497392A (en) Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use as in vivo immune modulators
AU2874389A (en) Sheet material used to form portions of fasteners
AU2782789A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB2196634B (en) Monoclonal antibodies to hiv and related peptides
GB2216134B (en) Membranes and methods of preparation thereof
AU1107188A (en) Monoclonal antibodies to glycopeptides of human cytomegalovirus
AU8015587A (en) 4-amino-3-hydroxybutyronitrile and preparation of preparation of n-alkyl-3-pyrrolidinols
AU7270387A (en) Enhanced expression of human interleukin-2 in mammalian cells
AU6373286A (en) Auto-anti-idiotypic monoclonal antibodies to steroid receptals and uses thereof
AU4485089A (en) Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr
AU3488089A (en) Process for the preparation of catalyst particles and catalyst particles thus prepared
AU3900489A (en) Substituted imidazolylmethyloxiranes and substituted imidazolylpropenes their preparation and fungicides containing them
IL84628A0 (en) Process and device for the cultivation of immobilized or adherent mammalian cells and their use in the preparation of proteins
AU1908395A (en) Antibodies to mammalian natural killer antigens and uses
AU6036690A (en) Human monoclonal antibodies to hiv-1mn gp 120
AU2622988A (en) Preparation and use of plants of improved biological value
AU3212589A (en) Medical material permitting cells to enter thereinto and artificial skin
AU7121487A (en) Methods and compositions relating to regression-associated antigens
GB2189810B (en) Antibodies their preparation and use and products containing them